These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 8498129)

  • 1. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
    Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC
    Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody against human ovarian tumor-associated antigens.
    Poels LG; Peters D; van Megen Y; Vooijs GP; Verheyen RN; Willemen A; van Niekerk CC; Jap PH; Mungyer G; Kenemans P
    J Natl Cancer Inst; 1986 May; 76(5):781-91. PubMed ID: 3517452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions.
    Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J
    Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
    Daste G; Gioanni J; Lauque D; Kremps M; Mazeau C; Paquis P; Schneider M
    Arch Anat Cytol Pathol; 1997; 45(4):185-91. PubMed ID: 9406475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytochemical staining of smears and corresponding cell blocks from serous effusions: a follow-up and comparative investigation.
    Jensen ML; Johansen P
    Diagn Cytopathol; 1996 Jul; 15(1):33-6. PubMed ID: 8807249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.
    Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB
    Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new epithelial membrane antigen (Calam 27) as a marker of carcinoma in serous effusions.
    Gioanni J; Caldani C; Zanghellini E; Mazeau C; Duplay H; Ferrua B; Schneider M
    Acta Cytol; 1991; 35(3):315-9. PubMed ID: 2042433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies.
    Flynn MK; Johnston W; Bigner S
    Acta Cytol; 1993; 37(4):439-47. PubMed ID: 8328236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M; Hoogsteden HC; Van der Kwast TH
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas.
    van Niekerk CC; Boerman OC; Ramaekers FC; Poels LG
    Am J Pathol; 1991 Feb; 138(2):455-63. PubMed ID: 1992770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Density distribution and immunological reactivity of tumor cells from peritoneal effusions of patients with ovarian neoplasms.
    Harłozińska A; Bar JK; Cisło M; Richter R; Rabczyński J
    Anal Cell Pathol; 1992 Jan; 4(1):1-12. PubMed ID: 1370907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in expression of differentiation markers between normal ovarian cells and derived tumors.
    Van Niekerk CC; Ramaekers FC; Hanselaar AG; Aldeweireldt J; Poels LG
    Am J Pathol; 1993 Jan; 142(1):157-77. PubMed ID: 7678716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
    Carico E; Chicchirichi R; Atlante M; Giovagnoli M; Vecchione A
    Anticancer Res; 1995; 15(2):631-4. PubMed ID: 7763049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
    Zhu W; Michael CW
    Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.
    Buist MR; Molthoff CF; Kenemans P; Meijer CJ
    J Clin Pathol; 1995 Jul; 48(7):631-6. PubMed ID: 7560169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.
    Boerman OC; van Niekerk CC; Makkink K; Hanselaar TG; Kenemans P; Poels LG
    Int J Gynecol Pathol; 1991; 10(1):15-25. PubMed ID: 2007534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.
    Boerman O; Makkink K; Massuger L; Thomas C; Kenemans P; Hanselaar T; Poels L
    Anticancer Res; 1989; 9(3):551-8. PubMed ID: 2764501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant ascites of serous papillary ovarian adenocarcinoma. An immunocytochemical study of the tumor cells.
    Guzman J; Hilgarth M; Bross KJ; Ross A; Wiehle U; Kresin V; Grunert F; von Kleist S
    Acta Cytol; 1988; 32(4):519-22. PubMed ID: 3041721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.